Vet drugmakers get Warning Letters too

Share this article:

The FDA's marketing folks care about our pets. Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.

The Food and Drug Administration found fault with website copy that said the drug is “potentially well-suited for treating non-oncology diseases, such as canine atopic dermatitis or feline asthma,” and that off-label use studies supported this supposition.

RF says the FDA also highlighted that its case against AB Science is “particularly compelling” because Kinavet's approval “explicitly prohibits a company from allowing its drug to be used outside of its approved labeling.”

The manufacturer also failed to include risk information, such as the warning that people should not touch the drug because of its association with birth defects and other problems.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters